Sequoia Capital Israel

Founded in 2008, Collibra provides an end-to-end Data Intelligence platform that accelerates digital business transformation. Its platform breaks down traditional data silos, enabling trustworthy business intelligence and facilitating collaboration among users.

Chime is a mobile banking and finance platform that automatically sets aside a predetermined amount into savings after transactions. It earns revenue from merchant transaction fees, aligning incentives and enabling users to avoid fees, save money, and lead healthier financial lives.

ServiceTitan is a cloud-based software provider for field service businesses, offering tools to streamline operations, enhance customer service, and drive growth. Its platform caters to industries such as HVAC, plumbing, electrician services, and more in the United States and Canada.

Outreach is a sales engagement platform that helps organizations manage and optimize interactions across email, voice, and social channels throughout the customer lifecycle. The platform uses machine learning to guide sales representatives to take the right actions, automate repetitive tasks, and personalize communications while tracking sales activity and performance. It supports account-based, outbound, and inbound sales, as well as sequence and task management, email and activity tracking, and insights that analyze buyer sentiment to optimize content and sequences in real time. By integrating automated alerts, collaboration features, and performance analytics, Outreach aims to increase the volume of qualified meetings and improve the efficiency and effectiveness of customer-facing teams.

Olive AI, Inc. specializes in developing artificial intelligence and robotic process automation solutions tailored for healthcare organizations. Founded in 2012 and based in Columbus, Ohio, the company offers an AI-as-a-Service platform that automates a variety of administrative workflows, including claim status checks, account updates, and prior authorizations. By streamlining these repetitive and high-volume tasks, Olive allows healthcare professionals to focus on more creative and empathetic aspects of patient care. The software acts as an intermediary between different systems and data, helping to reduce administrative errors and improve cash collections, ultimately enhancing overall efficiency and patient outcomes in the healthcare sector. Olive AI, Inc. was previously known as CrossChx, Inc. before rebranding in July 2018.

Toss is a South Korea-based mobile financial service platform developed by the fintech startup Viva Republica, established in 2011 by Seunggun Lee in Seoul. The platform offers a range of services aimed at simplifying financial management for users, including peer-to-peer money transfers, credit score management, and bank account oversight. Additionally, Toss provides access to loan and insurance plans, facilitates bill splitting, and supports QR payments. These features collectively enable users to handle their financial needs efficiently and conveniently.

Netskope is a cloud security company that provides a SaaS-based platform offering real-time data and threat protection for enterprises worldwide. Its key products include Netskope Security Cloud, Cloud XDTM, NewEdge security network, CASB, SWG, and professional services. Serving various industries such as financial services, government, healthcare, high-tech, manufacturing, and retail, Netskope enables secure access to cloud services, websites, and private applications from any device.

HealthKart is a company dedicated to providing health and nutritional supplements tailored to various demographics, including vegans, kids, and women. Their product range includes protein supplements, weight loss aids, hair care kits, and specialized foods and drinks. HealthKart enhances user convenience through its mobile app, which allows customers to easily discover and purchase fitness products directly from their devices. The company aims to support consumers in achieving their wellness and fitness goals by offering a comprehensive selection of health-related items.

Freshworks Inc. develops innovative software solutions designed to enhance customer engagement for businesses of all sizes. Founded in 2010 and headquartered in San Mateo, California, the company provides a suite of software-as-a-service products that cater to various business functions. Its offerings include Freshdesk for customer support, Freshsales CRM for sales management, Freshservice for IT service management, and Freshteam for recruitment and employee management. Additionally, Freshworks provides tools like Freshchat for customer interaction, Freshmarketer for marketing automation, and Freshcaller for cloud-based telephony. The company's solutions enable organizations to acquire, engage, and retain customers while offering a comprehensive view of customer interactions. Freshworks has a global presence with offices in multiple countries, including India, the UK, Australia, Germany, France, Singapore, and the Netherlands. Its commitment to delivering user-friendly software ensures a quick return on investment for its clients.

Moderna is a biotechnology company focused on messenger RNA therapeutics and vaccines. It develops mRNA-based medicines that instruct cells to produce therapeutic proteins or antibodies in vivo, targeting infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company has built a broad pipeline with multiple development candidates across several modalities and a track record highlighted by a COVID-19 vaccine authorized in the United States. Moderna collaborates with major pharmaceutical and research partners, including AstraZeneca, Merck, Vertex, and Alexion, as well as academic institutions such as Harvard University and Karolinska Institutet. It maintains manufacturing collaborations with Lonza for mRNA production and Catalent for fill-finish, and engages with public sector and philanthropic supporters such as BARDA, DARPA, and the Gates Foundation. As of 2025, the company continued expanding its mRNA development program across infectious disease, oncology, cardiovascular, and rare genetic diseases.